NC-KBI-BIOPHARM/ARGONAUT
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufacturing organization (CMO) serving the biopharmaceutical and diagnostics industries, today announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions. The arrangement provides a seamless integration of drug substance and drug product manufacturing by combining KBI’s leading drug development and biologics manufacturing services with Argonaut’s expertise in sterile fill-finish. The alliance reinforces both companies’ commitment to support customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116635207/en/
Biopharmaceutical organizations are expected to benefit from this strategic collaboration through accelerated timelines and the scalable manufacturing capacities offered by both organizations.
“At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development,” said J.D. Mowery, President and CEO of KBI Biopharma.
He continued, “Similarly, Argonaut has established itself as a trusted provider in the industry, known for its cutting-edge technologies and exceptional track record in drug product manufacturing. Their commitment to quality and efficiency aligns perfectly with our own values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry.”
“We believe this strategic alliance resolves a key issue for biopharmaceutical organizations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible, and leverages the unique expertise of our two organizations,” said Wayne Woodard, Founder and CEO of Argonaut. “Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products. With this collaboration, biopharmaceutical organizations can now seamlessly move from development to full-scale manufacturing, saving both time and capital expenditures.”
In January 2023, Argonaut announced a capital investment focused on the significant expansion of its Carlsbad, CA manufacturing facilities with increased capacity and scale, and this agreement with KBI furthers its commitment to continual growth.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
More information available at www.argonautms.com.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116635207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bridgepoint to Partner With ht.digital, the Leading Digital Asset Transparency Layer25.11.2025 09:00:00 CET | Press release
Bridgepoint to become majority shareholder in ht.digital, a London headquartered specialist provider of audit, accounting, assurance, operational and technology solutions to the digital asset ecosystem ht.digital has delivered organic revenue growth of c.100% over the last two years, scaling rapidly in a fast-growing market The partnership will accelerate ht.digital’s international expansion and continued investment in technology, talent and brand Bridgepoint, one of the world’s leading mid-market investors, today announced that it has agreed to acquire a majority stake in ht.digital, a leading, London-headquartered provider of digital asset assurance and technology solutions. The investment will be made by Bridgepoint Development Capital V – Bridgepoint’s lower middle-market fund focused on supporting fast-growing businesses across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125907148/en/ Digital assets – incl
Thredd Signs Landmark Agreement to Enable Visa Cloud Connect Globally25.11.2025 09:00:00 CET | Press release
Agreement sets stage for strengthened global reach, scalability, and resilience for fintechs and banks worldwide Thredd, a leading next-generation global payments processor, today announced that it has signed an agreement to enable Visa Cloud Connect on a global scale. This milestone reflects Thredd’s continued investment in cloud-first infrastructure and reinforces its role as a global technology leader in payments processing. Visa Cloud Connect allows organisations to access VisaNet, Visa’s secure and powerful global payments network, through their own cloud-based infrastructure. Purpose-built for cloud-native clients, Visa Cloud Connect can help deliver increased flexibility, faster time to market, and seamless scalability across borders. Under the agreement, Thredd will connect across three global Visa Cloud Connect endpoints, committing to a full global rollout. Once live, this will eliminate the need for multiple regional integrations, helping our clients gain new geographies and
Allvue Expands European Footprint, Names KPMG Luxembourg as Core Implementation Partner25.11.2025 08:56:00 CET | Press release
The partnership offers managers seamless access to specialized local expertise and regulatory knowledge, ensuring accelerated confidence in adopting world-class, API-first technology, including Allvue’s AI tool, Andi. Allvue Systems, LLC (“Allvue”), a leading software technology provider for the private capital markets, today announced an expansion of its current presence in EMEA, naming KPMG Luxembourg as its core implementation partner for all client deliverables for Europe. The strategic collaboration is designed to meet the growing demand from global asset managers leveraging Luxembourg as the premier European fund domicile. By aligning Allvue’s world-class, unified technology platform and solutions with KPMG’s renowned local expertise in private assets, deep regional relationships, and plurilingual delivery capabilities, the partnership offers clients a faster, more effective path to technology adoption. “Our mission is to make private markets more transparent, efficient, and conn
Datassential Expands Global Menu Intelligence with Debut of Global Launches25.11.2025 08:30:00 CET | Press release
Datassential, the leading global food and beverage intelligence platform, announced the debut of Global Launches, an expanded menu–tracking solution offering a unified view of new menu items and limited-time offers (LTOs) across major international markets. Global Launches now tracks menu innovation across hundreds of restaurant chains in the European, Latin American, and Asia-Pacific markets. Building on the robust menu tracking already available in the U.S. and Canada, this expansion gives foodservice businesses a comprehensive view of new menu items and LTOs around the globe, providing unmatched visibility into how trends and flavors appear across worldwide markets and evolve to fit local tastes. “Innovation doesn’t happen in one market at a time — it’s global, constant, and increasingly fast,” said Jim Emling, CEO of Datassential. “Global Launches now offers our customers a single, trusted source to see what’s launching across the world, how concepts are localized, and where the ne
Friendly Fraud Expected to Increase by 25% Between Thanksgiving and Cyber Monday, Warns ACI Worldwide25.11.2025 08:00:00 CET | Press release
ACI’s Payments Intelligence approach offers merchants complete journey protection—stopping friendly fraud and chargeback abuse in real timeACI expects industry leading fraud approval rate of 98% during holiday season - outperforming market averages 'Friendly fraud’ is expected to increase by 25% between Thanksgiving and Cyber Monday, according to an analysis of billions of transactions of global eCommerce businesses by ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. ‘Friendly fraud’ or ‘return fraud’ occurs when legitimate customers dispute transactions post-purchase. Often mistaken for true fraud, these disputes are a growing industry challenge and cost retailers $103 billion in 2024 alone, according to a recent industry report. The average transaction value for a ‘friendly fraud’ item during this year’s holiday season is expected to reach $291, $52 higher than during the same period last year, representing a 21% YoY increase. “These numbers are stag
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom